Tewari: microRNAs ~22nt, >1000 miRNAs known, wide-ranging biological roles esp for development / differentiation #FDA-AACR
9:22am July 19th 2016 via Hootsuite
Tewari: This field on the horizon; in the research phase. Bulk of time reviewing circulating miRNAs. then exRNA, in exosomes #FDA-AACR
9:21am July 19th 2016 via Hootsuite
Muneesh Tewari (Univ Mich) Extracellular RNA: a next frontier for liquid biopsy biomarkers #FDA-AACR
9:19am July 19th 2016 via Hootsuite
Q: Concern abt tech: is TP53 looked at? Clonal hematopoesis of indeterminate origin? A: At very low freq in landscape <0.01% #FDA-AACR
9:18am July 19th 2016 via Hootsuite
Park: '14 ref https://t.co/4rP4d0VU0b with PIK3CA for early-state br cancer. new prospective clinical trial at Hopkins #FDA-AACR
9:13am July 19th 2016 via Hootsuite
Park: If good post-surgery markers exist, better differentiation for those who need adjuvant Rx. #FDA-AACR
9:10am July 19th 2016 via Hootsuite
Park: 150K women are candidates (US number) for adjuvant Rx. Clear benefit, but not so great; evidence for overtreatment #FDA-AACR
9:09am July 19th 2016 via Hootsuite
Park: Explained via heterogeneity; tissue/blood of ESR1 can find different mutations. Now wants to look at early br cancer #FDA-AACR
9:08am July 19th 2016 via Hootsuite
Park: If a tissue was 3y away from blood discordant using BEAMing (w/ Sysmex-Inostics) <3y 100% concordant. #FDA-AACR
9:07am July 19th 2016 via Hootsuite
Park: They were one of the first using Streck; showing ddPCR on single PIK3CA exon 9/20 mutants; favorably cp against PAX BCT #FDA-AACR
9:06am July 19th 2016 via Hootsuite
Park: But the end-goal - clinical utilty. Very few biomarkers meet this standard - what we should be striving for #FDA-AACR
9:05am July 19th 2016 via Hootsuite
Park: ASCO pres Hayes 'A bad test can be just as dangerous as a bad drug.' Preanalytic/analytic validation. Clin validation. #FDA-AACR
9:04am July 19th 2016 via Hootsuite
Park: Shows duplex sequencing approach, cp to Safe-SeqS. Lays out steps to clinical practice next #FDA-AACR
9:03am July 19th 2016 via Hootsuite
Park: Shows BEAMing method '03 PNAS https://t.co/DzXsXpqd78 Shows Bio-Rand and RainDance approaches. NGS: limit of det vs # genes #FDA-AACR
9:01am July 19th 2016 via Hootsuite
Park: Shows a graphic of 100 or so figures of George Washington; one with a moustache. #FDA-AACR
8:59am July 19th 2016 via Hootsuite
Park: Reviews methods - BEAMing, other digital PCR methods; deep NGS (Taq-Seq, SAFE-SeqS, etc). Can also measure structural var #FDA-AACR
Park: Uses figure from this '13 review https://t.co/pj8O3XlSdu Points out cfDNA increases w/inflammation, organ rejection, GVHD #FDA-AACR
8:56am July 19th 2016 via Hootsuite
Ben Ho Park (Johns Hopkins MD) Cell-free DNA, uses and steps needed for clinical utjilty #FDA-AACR
8:53am July 19th 2016 via Hootsuite
Q: Cost? Scher: 'Not something I'd setup in my garage', notes evolution of technology. Single-cell datapoint makes him 'nervous' #FDA-AACR
8:47am July 19th 2016 via Hootsuite
Scher: Now CLIA-certified LDT at $GHDX in Calif #FDA-AACR
8:46am July 19th 2016 via Hootsuite
Scher: Even with one cell - AR-v7 is 100% spec (100% PPV) for de novo resistance; shorter time on drug, shorter rPFS, shorter OS #FDA-AACR
8:45am July 19th 2016 via Hootsuite
Scher: Frequency of detection of AR-v7 increases w/therapy; '16 JAMA Oncol https://t.co/OeAzfPrlQl Pts with AR-v7 did worse #FDA-AACR
8:44am July 19th 2016 via Hootsuite
Scher: By 3rd and 4th decision points, the 'biology at point A will differ from point B' #FDA-AACR
8:41am July 19th 2016 via Hootsuite
Scher: Focus on decision-points: 1st A or E hormal drug choice. 2nd decision - critical - change to chemo (taxane) or other drug #FDA-AACR
8:40am July 19th 2016 via Hootsuite
Scher: Observed clusters, small, CK-neg. Use mAb for AR splice var. Detects fluor signal on cell #FDA-AACR
8:39am July 19th 2016 via Hootsuite
Scher: Shows compares images from CellSearch compared to EPIC - non-traditional CTCs, small CTCs, CK-neg (likely EMT), speckled CK #FDA-AACR
8:38am July 19th 2016 via Hootsuite
Scher: '15 review https://t.co/NCuz5xsOwH test picked up by QIAGEN. Onto CTC, uses EPIC Sciences imaging platform #FDA-AACR
8:36am July 19th 2016 via Hootsuite
Scher: '15 review of AR gene https://t.co/PUtMHuPN34 splice var V7 predicts sens to abiraterone and enzalutamide #FDA-AACR
8:33am July 19th 2016 via Hootsuite
Scher: What tissue to use is the question, for non-castrate metastatic, and castration-R and MSKCC IMPACT ONCOPRINT; focus on CTC #FDA-AACR
8:32am July 19th 2016 via Hootsuite
Scher: Prior response to one hormonal drug doesn't predict efficacy of second; waterfall plot shown; and when to use chemo #FDA-AACR
8:29am July 19th 2016 via Hootsuite
Scher: Prostate ca overview - rising PSA, castration-resistance, since '10 now 6 drugs; '00 review https://t.co/50yaO36E2h #FDA-AACR
8:27am July 19th 2016 via Hootsuite
Howard Scher (MSKCC NY) Dev of an ARv7 predictive biomarker test on CTC from analytical validation to clinical utility #FDA-AACR
8:25am July 19th 2016 via Hootsuite
Blumenthal and Janne intro remarks - for drug and device dev workshop, ambitious agenda, will include recent cobas EGFR ctDNA #FDA-AACR
8:23am July 19th 2016 via Hootsuite
Today's #FDA-AACR liquid biopsy workshop agenda (PDF) https://t.co/FtpaNhG3d8
8:20am July 19th 2016 via Hootsuite
Today live-tweets from @AACR and @US_FDA liquid biopsy workshop, available by webcast. https://t.co/qPsNPt4d51 Will use #FDA-AACR tag.
8:19am July 19th 2016 via Hootsuite
RT @aacr: .@US_FDA and AACR co-sponsoring liquid biopsy workshop, available by webcast. https://t.co/qPsNPt4d51 https://t.co/NLLgmQKL5Z
8:17am July 19th 2016 via Hootsuite
Circulating Tumor DNA Shorter Than Circulating Normal DNA, Study Finds | GenomeWeb https://t.co/XKDWg9iYJI
8:05am July 19th 2016 via Hootsuite
FDA Releases Draft Guidance Outlining Principles of Drug/Diagnostic Codevelopment | GenomeWeb https://t.co/QpCzb7F9Le
7:05am July 19th 2016 via Hootsuite
Public-Health Officials Across U.S. Race to Build Defenses Against Zika Virus - WSJ https://t.co/o9KAiy4GrP
5:51am July 19th 2016 via Hootsuite
Children's hospital using 'Pokemon Go' to get patients out of bed https://t.co/8CDH0NFYsb
5:19am July 19th 2016 via Hootsuite
AstraZeneca wants to advance lung cancer drug after hitting PhIII target | FierceBiotech https://t.co/XUxblIFK9t
3:45pm July 18th 2016 via Hootsuite
Illumina - DNA Sequencing Applications And The Holy GRAIL | Seeking Alpha https://t.co/Jc4JTWDMto
10:31am July 18th 2016 via Hootsuite
CoreGenomics: Whole genome amplification improved https://t.co/Ir0JS7Qbyc
8:30am July 17th 2016 via Hootsuite
RT @davidharvey: Get off my lawn, Pokemon Go edition https://t.co/ZwVmOIKmpd
7:05am July 17th 2016 via Twitter Web Client
Obituary: Investor Larry Bock Helped Launch Dozens of Biotechs - WSJ https://t.co/lKUuPF3A0H
6:36am July 17th 2016 via Hootsuite
The scientific case for bribing your kids - The Washington Post https://t.co/IyOSZFVDlT
5:10pm July 15th 2016 via Hootsuite
MT @EricTopol: #crowdsourcing biomedical research data -> knowledge https://t.co/njulKjZeZ5 @NatureRevGenet https://t.co/u2STlFuKRg
4:35pm July 15th 2016 via Hootsuite
Fascinating work - cells controlling mito division via the ER https://t.co/TJKhqtiHpA
3:35pm July 15th 2016 via Hootsuite
RT @NatureNews: Most popular this week: How China is rewriting the book on human origins https://t.co/k8TLUaKVMF https://t.co/leDsJyMLhU
2:30pm July 15th 2016 via Hootsuite
Webinar July 28: Breakthrough Cancer Genomics Sequencing Technology | TOMA Biosciences https://t.co/LkyRB2nHmi
1:20pm July 15th 2016 via Twitter Web Client
